CA2309504C - Dispositif et procede de dosage autonome - Google Patents
Dispositif et procede de dosage autonome Download PDFInfo
- Publication number
- CA2309504C CA2309504C CA002309504A CA2309504A CA2309504C CA 2309504 C CA2309504 C CA 2309504C CA 002309504 A CA002309504 A CA 002309504A CA 2309504 A CA2309504 A CA 2309504A CA 2309504 C CA2309504 C CA 2309504C
- Authority
- CA
- Canada
- Prior art keywords
- assay device
- housing
- specimen
- specimen holder
- chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003556 assay Methods 0.000 title claims abstract description 226
- 238000000034 method Methods 0.000 title claims description 20
- 239000012491 analyte Substances 0.000 claims abstract description 61
- 230000002093 peripheral effect Effects 0.000 claims abstract description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 118
- 239000012528 membrane Substances 0.000 claims description 85
- 238000006243 chemical reaction Methods 0.000 claims description 45
- 230000000717 retained effect Effects 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 31
- 239000002775 capsule Substances 0.000 claims description 27
- 229920003023 plastic Polymers 0.000 claims description 24
- 239000004033 plastic Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 18
- 239000011148 porous material Substances 0.000 claims description 7
- 238000004891 communication Methods 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 239000000463 material Substances 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 239000013641 positive control Substances 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 230000009870 specific binding Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 239000013642 negative control Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 239000003446 ligand Substances 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000005252 hepatitis A Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000012780 transparent material Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 201000005505 Measles Diseases 0.000 description 4
- 208000005647 Mumps Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 208000010805 mumps infectious disease Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 201000005404 rubella Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- HZBQEERHMBZTTE-UHFFFAOYSA-N 4-ethyl-2-[2-(4-ethyl-6-sulfo-1,3-benzothiazol-2-yl)hydrazinyl]-1,3-benzothiazole-6-sulfonic acid Chemical compound N1C2=C(CC)C=C(S(O)(=O)=O)C=C2SC1=NN=C1SC(C=C(C=C2CC)S(O)(=O)=O)=C2N1 HZBQEERHMBZTTE-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000013138 Drug Receptors Human genes 0.000 description 1
- 108010065556 Drug Receptors Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010002724 Pheromone Receptors Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 239000002427 pheromone receptor Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0633—Valves, specific forms thereof with moving parts
- B01L2400/0644—Valves, specific forms thereof with moving parts rotary valves
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
La présente invention concerne un analysat ou des analysats autonomes, comprenant des bioanalysats, lequel comprend un premier logement et un support à échantillon monté rotatif dans le premier logement. Le support à échantillon présente une partie centrale, un bord circulaire entourant la partie centrale et une broche s'étendant à partir du dessous de la partie centrale. La partie centrale présente une fente radiale s'étendant de son extrémité périphérique vers une extrémité fermée, ou alternativement vers son centre. Un ensemble à ressort/de verrouillage est adapté pour être maintenu dans la fente sur le support d'échantillon et il comprend un ressort disposé dans la fente près de son extrémité fermée, ou alternativement près du centre de la partie centrale, et un élément de verrouillage présentant une extrémité distante ainsi qu'une pluralité de plongeurs. Le dispositif de dosage comprend également un second logement, de préférence un plateau-came présentant une partie de jante entourant une partie concave adaptée pour recevoir la partie centrale du support d'échantillon ainsi qu'une ouverture sur la partie de jante permettant d'ajouter un échantillon à tester.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/969,177 | 1997-11-12 | ||
| US08/969,176 US6120733A (en) | 1997-11-12 | 1997-11-12 | Self-contained assay device |
| US08/969,176 | 1997-11-12 | ||
| US08/969,177 US5817522A (en) | 1997-11-12 | 1997-11-12 | Self-contained assay device and method |
| PCT/US1998/024160 WO1999024813A1 (fr) | 1997-11-12 | 1998-11-12 | Dispositif et procede de dosage autonome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2309504A1 CA2309504A1 (fr) | 1999-05-20 |
| CA2309504C true CA2309504C (fr) | 2005-12-13 |
Family
ID=27130525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002309504A Expired - Lifetime CA2309504C (fr) | 1997-11-12 | 1998-11-12 | Dispositif et procede de dosage autonome |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1032820A4 (fr) |
| AU (1) | AU1404099A (fr) |
| CA (1) | CA2309504C (fr) |
| WO (1) | WO1999024813A1 (fr) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3713779A (en) * | 1970-12-07 | 1973-01-30 | J Sirago | Disposable comparison detector kit |
| ES2057904T3 (es) * | 1990-06-15 | 1994-10-16 | Chiron Corp | Conjunto y aparato de ensayo, autonomos y completos en si mismos. |
| EP0504432A4 (en) * | 1990-10-09 | 1993-05-05 | Idemitsu Petrochemical Co. Ltd. | Method of immunological quantitative analysis |
| US5288463A (en) * | 1992-10-23 | 1994-02-22 | Eastman Kodak Company | Positive flow control in an unvented container |
| US5501837A (en) * | 1994-07-15 | 1996-03-26 | Sayles; Philip W. | One-step test device |
| US5639424A (en) * | 1995-11-08 | 1997-06-17 | Rausnitz; Gerald J. | Portable fertility tester |
-
1998
- 1998-11-12 EP EP98957891A patent/EP1032820A4/fr not_active Withdrawn
- 1998-11-12 WO PCT/US1998/024160 patent/WO1999024813A1/fr not_active Ceased
- 1998-11-12 CA CA002309504A patent/CA2309504C/fr not_active Expired - Lifetime
- 1998-11-12 AU AU14040/99A patent/AU1404099A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999024813A1 (fr) | 1999-05-20 |
| AU1404099A (en) | 1999-05-31 |
| CA2309504A1 (fr) | 1999-05-20 |
| WO1999024813A8 (fr) | 1999-07-29 |
| EP1032820A4 (fr) | 2006-05-10 |
| EP1032820A1 (fr) | 2000-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6120733A (en) | Self-contained assay device | |
| EP1388006B1 (fr) | Dispositif d'essai en ligne et procedes d'utilisation | |
| AU2003266153B2 (en) | In line test device and methods of use | |
| AU605257B2 (en) | Self-contained immunoassay element | |
| US5817522A (en) | Self-contained assay device and method | |
| US4859610A (en) | Immunoassay incubation device | |
| CA1189431A (fr) | Cuve de reaction multizone dotee d'un dispositif de commande interzones actionnable par pression | |
| CA2416886C (fr) | Dispositif d'acheminement de reactifs et procede d'utilisation | |
| DK165957B (da) | Apparat med et antal separate reagenskamre, der successivt indeholder de til en analytisk bestemmelse noedvendige reagenser | |
| US5427739A (en) | Apparatus for performing immunoassays | |
| KR20000048669A (ko) | 화학 분석 장치 및 방법 | |
| WO2008061130A2 (fr) | Dispositif amélioré de recueil et d'essai et sa méthode d'utilisation | |
| CA2889492C (fr) | Dispositif de test autonome | |
| CA2309504C (fr) | Dispositif et procede de dosage autonome | |
| EP0204579A2 (fr) | Dispositif d'incubation des essais immunologiques | |
| MXPA00004669A (en) | Self-contained assay device and method | |
| AU2002256397B2 (en) | In line test device and methods of use | |
| AU2002256397C1 (en) | In line test device and methods of use | |
| AU2002256397A1 (en) | In line test device and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20181113 |